EVGN — Evogene Ltd.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1574565 ·
Last close
$0.42
Market Cap
$6.64M
52W High
$1.50
52W Low
$0.37
ADV30
225,277
Next earnings
2026-11-19
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 347,000 | 141,000 | -2,563,000 | -1,768,000 | 13,440,000 | 9,316,000 | 7,672,000 |
| Mar 2026 | — | — | — | — | 17,948,000 | 8,511,000 | 9,958,000 |
| Dec 2025 | 314,000 | -1,970,000 | -5,212,000 | -5,309,000 | 20,046,000 | 12,956,000 | 8,071,000 |
| Sep 2025 | 312,000 | 155,000 | -2,724,000 | 3,874,000 | 26,086,000 | 5,626,000 | 8,834,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,815,000
Investing CF
$-2,047,000
Financing CF
$-3,223,000
CapEx
$-16,000
Dividends Paid
$-193,000
Buybacks
—
EPS Diluted TTM
$-1.39
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-288,426,000
Inventory
$175,000
Receivables
$1,702,000
ST Investments
$4,543,000
EBIT TTM
$-13,919,000
Pretax Income TTM
$-17,500,000
Interest Exp TTM
$3,581,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,657,000
EBITDA
$-13,971,000
Free Cash Flow
$-2,041,250
Enterprise Value
$8,341,558
Total Cash
$9,316,000
Total Debt
$2,101,000
Shares Out
15,801,407
Trailing EPS
$-1.75
Book Value
$-0.24
ROE
-182.7%
ROA
-37.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,853,000 | -14,034,000 | -8,485,000 | 20,046,000 | 8,071,000 | -82,000 | -13,502,000 |
| Dec 2024 | 5,577,000 | -18,757,000 | -16,485,000 | 39,864,000 | 25,026,000 | -1,451,000 | -19,700,000 |
| Dec 2023 | 2,982,000 | -22,205,000 | -23,879,000 | 51,101,000 | 22,416,000 | 12,053,000 | -21,577,000 |
| Dec 2022 | 1,675,000 | -26,941,000 | -26,638,000 | 56,126,000 | 21,336,000 | 27,930,000 | -23,678,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GWTI | GREENWAY TECHNOLOGIES, INC. & SUBSIDIARIES | $6.28M | $0.01 | — |
| BON | Bon Natural Life Ltd | $7.32M | $1.20 | — |
| GURE | GULF RESOURCES, INC. | $5.91M | $3.26 | — |
| GLUC | Glucose Health, Inc. | $8.30M | $0.31 | — |
| YCBD | cbdMD, Inc. | $5.24M | $0.47 | — |
News headlines (Yahoo Finance, 1h cache)
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
2026-08-31 12:00 · Yahoo
Evogene (EVGN) Q2 2026 Earnings Call Transcript
2026-08-25 11:45 · Yahoo
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
2026-08-25 11:00 · Yahoo
Evogene Ltd. Q2 2026 Earnings Call Summary
2026-08-19 12:30 · Yahoo
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
2026-08-14 11:00 · Yahoo
Evogene and ELEO to develop new oral PCSK9 inhibitors
2026-07-23 10:06 · Yahoo
EverGen Infrastructure Reports Q2 2026 Results
2026-08-27 04:26 · Yahoo
EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026
2026-08-26 21:00 · Yahoo
Evogene Ltd (EVGN) (Q2 2026) Earnings Call Highlights: Strategic Pivot to AI-Driven Drug ...
2026-08-18 21:01 · Yahoo
Evogene Reports Second Quarter and First Half 2026 Financial Results
2026-08-18 12:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.